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The search for the marker in sepsis and inflammation
continues. Perhaps when we do find it we may be able to
alter and influence the underlying pathophysiology of sepsis.
Many reports from those who believe that this may lie in the
hypothalamic–pituitary–adrenal axis have recently been
published. Manglik and colleagues [1] looked into secondary
adrenocortical insufficiency in patients who present with
severe sepsis. Measuring maximal cortisol secretion after
stimulation with adrenocorticotrophic hormone, those
investigators found that 9% of their population failed an
adrenocorticotrophic hormone stimulation test. Four per cent
had previously undiagnosed pituitary disease and 5% were
suffering from sepsis-related adrenal dysfunction. They used
absolute cortisol levels and not delta cortisol to define
adrenocortical insufficiency, but until we have an established
definition for adrenocortical insufficiency in sepsis the studies
will continue to yield disparate results.
Looking at reduced endogenous steroid levels in sepsis,
Marx and coworkers [2] focused on the androgens
dehydroepiandrosterone (DHEA) and its sulphated precursor
(DHEAS) and looked at disparity between survivors and
nonsurvivors from severe sepsis. The cortisol levels of
survivors reached upper normal limits and decreased
significantly toward late sepsis. However, nonsurvivors had
persistently lower cortisol levels (but within the normal
physiological range) throughout sepsis. DHEAS paralleled
this in survivors, with normal early levels reducing in late
sepsis, but in nonsurvivors levels were persistently low
throughout and to a significant degree. Survivors had
persistently elevated levels of DHEA as compared with
nonsurvivors. Marx and coworkers showed that relative
adrenocortical insufficiency extends to androgens, that
DHEA and DHEAS changes do not parallel each other, and
that DHEAS levels may even predict survival in severe sepsis,
which APACHE (Acute Physiology and Chronic Health
Evaluation) scores do not.
So will stress doses of hydrocortisone attenuate severe
systemic inflammatory response syndrome after cardiac
surgery with cardiopulmonary bypass? Kilger and coworkers
[3] would suggest that in high-risk patients this is so. They
found that severe systemic inflammatory response syndrome
(serum interleukin-6 concentration >1000pg/ml) was best
predicted in their population by a bypass time in excess of
97min and cardiac ejection fraction below 40%. Thus, by
targeting their predefined high-risk patients to receive
hydrocortisone, they showed recipients to have significantly
lower interleukin-6 levels, reduced duration of ventilation and
catecholamine support, and reduced duration of stay in the
intensive care unit and the hospital. Nothing yet suggests a
mortality benefit though.
Increased tissue factor is produced as part of the septic
inflammatory process because the coagulation cascade is
activated too. Carraway and coworkers [4] have already
shown that pretreating baboons with active site-inactivated
factor VII and tissue factor pathway inhibitor at the onset of
sepsis attenuates organ injury and is protective for lung and
kidney. They have now shown that similarly blocking tissue
factor in established Gram-negative sepsis will attenuate this
damage [5]. Using a baboon model again, they blocked
coagulation cascade initiation using active site-inactivated
factor VII at the time of first antibiotic therapy after inducing
sepsis. This resulted in reduced acute lung injury, renal injury,
metabolic acidosis and sepsis-induced coagulopathy. Can
we manipulate this therapeutically in human sepsis? Time
and more research will tell.
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Moving away from direct involvement of the inflammation/
coagulation process, Soliman and colleagues [6] looked at
how the ionized portion of serum magnesium varies in the
critically ill. They found that ionized magnesium level at
presentation did not affect outcomes (two-thirds of their
population had normal levels), but that the development of
reduced levels of ionized magnesium while in intensive care
was associated with higher mortality and more severe organ
dysfunction. Sepsis was an independent risk factor for
ionized hypomagnesaemia, but Soliman and colleagues
postulated that prolonged disease and diuretic administration
may also be contributory. It may be that low levels contribute
to critical illness, or that just the converse is true. Which is
true is unclear. What we need now is to discover how
magnesium supplementation will alter these findings.
Inappropriate ventilatory strategies for patients with acute
respiratory distress syndrome (ARDS) may have more
consequences for the recipient than just lung abnormalities.
Imai and colleagues [7] indicated that remote cellular
damage also occurs and that this may contribute to the
multiple organ dysfunction that often accompanies ARDS.
They looked at end-organ epithelial cell apoptosis in a rabbit
model of ARDS and at the effects of plasma on epithelial
cells from recipients of the injurious ventilatory strategy, and
analyzed samples from a previous trial into lung protective
ventilation [8]. They showed that kidney and small intestine
damage occurred when ventilation with high tidal volumes
and low positive end-expiratory pressures were used, and
that plasma from rabbits in this group would induce
apoptosis in cells in vitro. The Fas–Fas ligand system is
involved in cell apoptosis, and they found elevated levels of
soluble Fas ligand in human patients who had not received a
protective ventilatory strategy, which correlated well with
elevations in creatinine levels. Choosing the right ventilation
strategy for ARDS patients has more benefits than just lung
protection, and therapeutic targeting of these factors that
induce end organ apoptosis may be the next step.
Choosing the right ventilation strategy may not be the only
way to avoid lung problems in patients with ARDS. Desirable
strategies involve the prevention of over-distended alveoli
and their de-recruitment. Thus, it is not unreasonable to
consider that periodic endotracheal suctioning might
undermine these benefits. Maggiore and colleagues [9] set
out to find out whether this was so in patients with acute lung
injury, and considered preventative measures. They found
that closed suctioning systems reduced large lung volume
falls and preserved positive end-expiratory pressure induced
recruitment. Recruitment was augmented by performing
recruitment manoeuvres at the time of suctioning. Repetitive
shearing stresses on alveoli are injurious, and this study
shows some ways to prevent this.
Using inhaled nitric oxide (NO) in patients with ARDS
improves oxygenation, but it has not been proven to improve
outcome. Why is this so? Gerlach and coworkers [10]
looked at dose–response characteristics when long-term NO
is used and found that these characteristics changed.
Patients could become sensitized to NO, such that the
number of responders to low NO doses increased and some
became nonresponders at higher NO doses. It would seem
that constant dose NO is not right for all patients throughout
their treatment, and that there is more inter-patient and intra-
patient NO dose–response variability than we had thought.
Titrating doses at each step may improve long-term benefits
from NO therapy.
With respect to inotropes, which one should we use? The
debate continues. De Backer and colleagues [11] compared
inotropes and their effects on the splanchnic circulation in
sepsis. Dopamine was used and then substituted for either
adrenaline (epinephrine) or noradrenaline (norepinephrine) to
achieve or maintain adequate arterial pressures depending
on shock severity. The three inotropes were comparable in
moderate shock, and dopamine would actually appear to
have modest benefits for splanchnic circulation. However, in
more severe septic shock adrenaline impaired splanchnic
circulation, and De Backer and colleagues suggested that it
should be avoided in high doses in these patients. A larger,
truly randomized trial should determine whether they are
correct. However, if you use low dose dopamine in critically ill
patients for renal protection, Holmes and Walley [12] tell us
that the practice should be, “relegated to the place of high-
tidal volume ventilation and liberal transfusion practices”.
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